ATTR-ACT shows treatment breakthrough in amyloid cardiomyopathy
MUNICH – Tafamidis is the first-ever disease-modifying therapy for this rapidly progressive and underdiagnosed form of cardiomyopathy.
From the Journals
Spinraza shows motor improvements in older children with SMA type 1
Childhood Neuromuscular Disease as a Metaphor for the Scientific Advances in Child Neurology of the Last Quarter Century
John B. Bodensteiner, MD
Dr. Bodensteiner is Director of the American Board of Psychiatry and...
Spinal muscular atrophy added to newborn screening panel recommendations
It is estimated that national screening will avert 33 annual deaths and 48 annual cases of ventilator dependence.
Myelin antibody predicts ADEM relapse
LOS ANGELES – Could results help to guide decisions on immunosuppressive treatment?
Mohammed Sanjak, PhD
Dr. Sanjak describes a proposed test for assessing lower-limb muscle strength in patients with ALS.
VIDEOS: High-priced drugs, out-of-pocket costs raise challenges for neurologists
LOS ANGELES – Members of the AAN Neurology Drug Pricing Task Force spoke about the issues that arise in getting patients access to high-cost drugs...
FDA approves subcutaneous immunoglobulin treatment for CIDP
Hizentra is the first FDA-approved subcutaneously administered human immunoglobulin maintenance therapy for CIDP.
The case for being open-minded about medical marijuana
LAS VEGAS – As part of an open approach, educate patients about effective alternative treatments to medical cannabis, an expert advises.
Conference News Roundup—Association of Academic Physiatrists
A person with a spinal cord injury can improve his or her ability to grip and move household objects by using an electrical stimulation device...
From the Journals
Mogamulizumab active in HTLV-1–associated myelopathy
The phase 1-2a study shows potential for mogamulizumab in the treatment of HAM-TSP.